Shang Hai Zheng Quan Bao·2025-12-29 19:16Core Viewpoint - 九州通医药集团股份有限公司's wholly-owned subsidiary, Hubei Jiuzhou Industrial Park Operation Management Co., Ltd., has successfully completed the restructuring investment in Aoyuan Meigu Technology Co., Ltd., with the restructuring plan approved and executed as of December 29, 2025 [4][10]. Group 1: Restructuring Investment Overview - On April 23, 2025, 九州通's subsidiary signed a restructuring investment agreement with Aoyuan Meigu and its temporary administrator, committing to invest CNY 673.2 million for 360 million shares post-restructuring [2][5]. - A supplementary agreement was signed on September 24, 2025, adjusting the investment plan, with the number of shares to be acquired increased to 435,930,312 shares for a total investment of CNY 706.207 million [6]. Group 2: Court Proceedings and Restructuring Plan - On November 14, 2025, the Xiangyang Intermediate People's Court accepted Aoyuan Meigu's restructuring application and appointed a management team [3][7]. - The court approved the restructuring plan on December 16, 2025, leading to the termination of the restructuring process [4][11]. - The restructuring process was officially concluded on December 29, 2025, with all obligations under the restructuring plan fulfilled [8][9]. Group 3: Impact on Company Operations and Financials - The restructuring investment aligns with the company's long-term strategic development, enhancing its core competitiveness and enabling collaboration in the beauty and health sector [10]. - The completion of the restructuring is not expected to have a significant short-term impact on the company's financial performance, and there are no adverse effects on the interests of the company and its shareholders [11].